CRMD vs CTMX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CRMD · CorMedix$5.32 ▲ 1.72%
CTMX · CytomX$2.19 ▲ 2.34%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CRMD -52.0%
- CTMX -47.7%
Head to head
| Metric | CRMD | CTMX |
|---|---|---|
| Price | $5.32 | $2.19 |
| Change today | ▲ 1.72% | ▲ 2.34% |
| Market cap | $414.66M | $477.43M |
| Return, 3 months | -29.3% | -36.3% |
| Return, year to date | -54.3% | -48.6% |
| Return, 1 year | -50.6% | -39.5% |
| P/E (TTM) | 2.4 | – |
| P/B | 0.9 | 1.7 |
| P/E percentile vs own 5y | 70th | 25th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +149.9% | -92.4% |
| Net profit growth (YoY) | +31.1% | -13,319.5% |
| Gross margin | 82.6% | – |
| Operating margin | 47.5% | -476.2% |
| Net margin | 40.7% | -435.2% |
| Return on equity | 54.6% | -37.8% |
| Analyst target vs. price | +172.6% | +493.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 27 | 41 |
| 30-day volatility | 96.1% | 67.9% |
| Max drawdown, 1 year | -58.9% | -68.3% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CTMX is the largest of the group by market value.
- CTMX has returned the most over the past year.
- CRMD is growing revenue fastest.
- CRMD keeps the most profit per dollar of sales.
- CTMX has been the calmest stock over the last 30 days.